This isn’t FISHER WALLACE LABORATORIES’s most recent raise. Reg CF · Common Stock · Oct 2026 (Open) is more current.View latest round
via DealMaker · last checked Sep 30, 2026
Raised
$536.3K
54% of ceiling
Investors
—
—
Post-money valuation
$102.7M
pre-money + amount raised
Financials disclosed in this offering
FY2021–FY2022 · hover for source$4.2M
−$3.3M
FY2021
$4.7M
−$7.1M
FY2022
RevenueNet income
Metric
FY2021 audited
FY2022 audited
Income statement
Revenue
$4,230,290
$4,739,387
Cost of goods sold
$623,703
$1,096,113
Gross margin
85%
77%
Net income
-$3,262,291
-$7,073,744
Taxes paid
$250
$0
Balance sheet
Cash
$1,929,380
$128,229
Accounts receivable
$0
$0
Total assets
$1,999,403
$439,495
Short-term debt
$966,198
$0
Long-term debt
$576,525
$0
Total liabilities
$1,542,723
$4,664,010
Other
Headcount
12
12
The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Deal terms
Pre-money$102.2M
Post-money$102.7M
Price / share$10.99
Shares offered90,990
Offering details
Target$999,980
Max—
Min investment—
OpenedNov 2, 2023
DeadlineNov 30, 2023
ClosedNov 30, 2023
Days active28
Links & provenance
Source: SEC EDGAR
0001787792-23-000001
Last synced Sep 30, 2026
0001787792-23-000001
Last synced Sep 30, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.